Omaveloxolone for Friedreich Ataxia: a systematic review
HTA Journal · 04.08.2026 · 1 (1) · 41-51
DOI: 10.67516/htaj.26.1.41 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HTA Journal, online erschienen am 04.08.2026. Verfasst von Verônica Colpani und 9 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Friedreich ataxia (FA) is a progressive neurodegenerative disorder with significant morbidity and no established disease-modifying therapies. Omaveloxolone, a novel activator of the Nrf2 pathway, targets core disease mechanisms, yet prior evidence relies on non-randomized or early-phase studies. This systematic review aims to evaluate the efficacy and safety of omaveloxolone for individuals with FA based on evidence from randomized controlled trials (RCTs).
Methods
We conducted a systematic review in accordance with the Cochrane Handbook and reported it following the PRISMA 2020. The protocol was prospectively registered in PROSPERO (CRD420251115635). Eligible RCTs compared omaveloxolone versus placebo or standard care in genetically confirmed FA. Only RCTs evaluating the approved dose of omaveloxolone (150 mg/day) were considered for the primary analysis. We performed systematic searches across 7 databases and two clinical trial registers without language or date restrictions. Two review authors independently screened titles and abstracts, extracted data, assessed risk of bias using the Cochrane tool, and evaluated the certainty of evidence using the GRADE framework.
Results
We identified three RCTs; however, only one multicenter, phase II, double-blind trial (103 participants aged 16–40 years) evaluated the marketed dose and reported complete 48-week results. Low-certainty evidence indicates that omaveloxolone provides little to no improvement in neurological severity (MD –2.40; 95% CI –4.24 to –0.56) and may increase the risk of serious adverse events (RR 1.75; 95% CI 0.43–6.75), while probably having little or no effect on the risk of any adverse events (RR 1.00; 95% CI 0.96–1.04). Omaveloxolone shows minimal to no effects on dexterity, gait speed, or activities of daily living.
Conclusion
Based on the current limited evidence from RCTs, omaveloxolone appears to offer minimal clinical benefit for neurological function and daily activities in FA, with uncertainty surrounding the risk of serious adverse events. Larger, long-term trials are needed to better define the role of omaveloxolone in the management of Friedreich ataxia.
Zitieren
APA
Colpani, V., Parreira, P. D. C. S., Araújo, B. C. D., Stein, C., Cruz, C. M., Latorraca, C. D. O. C., Toledo, I. P. D., Silva, R. B., Pacheco, R. L., & Riera, R. (2026). Omaveloxolone for Friedreich Ataxia: a systematic review. HTA Journal, 1(1), 41-51. https://doi.org/10.67516/htaj.26.1.41
Vancouver
Colpani V, Parreira PDCS, Araújo BCD, Stein C, Cruz CM, Latorraca CDOC, et al. Omaveloxolone for Friedreich Ataxia: a systematic review. HTA Journal. 2026;1(1):41-51. doi:10.67516/htaj.26.1.41
BibTeX
@article{Colpani2026,
author = {Colpani, Verônica and Parreira, Patrícia do Carmo Silva and Araújo, Bruna Carolina de and Stein, Cinara and Cruz, Camila Monteiro and Latorraca, Carolina de Oliveira Cruz and Toledo, Isabela Porto de and Silva, Roberta Borges and Pacheco, Rafael Leite and Riera, Rachel},
title = {Omaveloxolone for Friedreich Ataxia: a systematic review},
journal = {HTA Journal},
year = {2026},
volume = {1},
number = {1},
pages = {41--51},
doi = {10.67516/htaj.26.1.41}
}
EUVIMED